Md Razi Ahmad1*, Md Najibur Rahman2, Jamal Akhtar3, Akhtar Hussain Farooqui4.
1Dept. of Moalijat, Salfia Unani Medical College & Hospital Laheriasarai Darbhanga, Bihar, INDIA.
2Dept. of Moalejat, Govt. Tibbi College & Hospital, Patna, Bihar, INDIA.
3Dept. of Moalejat, Z.V.M. Unani Medical College & Hospital, Pune, M.S., INDIA.
4Dept. of Moalejat, Z.V.M. Unani Medical College & Hospital, Pune, M.S., INDIA.
ORIGINAL RESEARCH ARTICLE
Volume 5 (Issue 3), Page 189-194.
*Author for correspondence
E-mail: [email protected]
ABSTRACT
Background: The concept of Hyperlipidaemia (Fart-e-Tadassum-Fid-Dam) is new and based on the biochemical changes in the blood i.e. distributed lipid metabolism and as a result, there is an increasing concentration of lipids in the blood. It was a prospective open-label randomized clinical study of Safoof-e-Mohazzil in the cases of primary hyperlipidemia (Fart-e-Tadassum-Fid-Dam).
Subjects and methods: All patients were randomly divided into two groups (test group and standard group). The patients of test groups were received Safoof-e-Mohazzil 05 gram OD in morning and the standard group were received Atorvastatin (Atorva) 10 mg OD (HS).
Results: All the baseline parameters were patients divided did not differ significantly between two intervention groups. After Intervention comparing to the test group v/s standard group, improvement of subjective parameters did not differ significantly. On objective parameters, improvement is very significant in both groups. All the biochemical parameters in each intervention groups P=0.001. On the comparison between test group v/s standard group by using unpaired âtâ test.
Conclusion: This result suggesting the effect of test drug and the standard drug is not equally effective. Test drug is more effective than control drug for the increment on HDLc, lowering of BMI and WHR. The HDL Cholesterols considered as good Cholesterols and lowering of BMI and WHR so this is also the beneficial effect of the test drug.
Keywords: Hyperlipidaemia, Fart-e-Tadassum-Fid-Dam, Safoof-e-Mohazzil, Atorvastatin, BMI, WHR.
Background: The concept of Hyperlipidaemia (Fart-e-Tadassum-Fid-Dam) is new and based on the biochemical changes in the blood i.e. distributed lipid metabolism and as a result, there is an increasing concentration of lipids in the blood. It was a prospective open-label randomized clinical study of Safoof-e-Mohazzil in the cases of primary hyperlipidemia (Fart-e-Tadassum-Fid-Dam).
Subjects and methods: All patients were randomly divided into two groups (test group and standard group). The patients of test groups were received Safoof-e-Mohazzil 05 gram OD in morning and the standard group were received Atorvastatin (Atorva) 10 mg OD (HS).
Results: All the baseline parameters were patients divided did not differ significantly between two intervention groups. After Intervention comparing to the test group v/s standard group, improvement of subjective parameters did not differ significantly. On objective parameters, improvement is very significant in both groups. All the biochemical parameters in each intervention groups P=0.001. On the comparison between test group v/s standard group by using unpaired âtâ test.
Conclusion: This result suggesting the effect of test drug and the standard drug is not equally effective. Test drug is more effective than control drug for the increment on HDLc, lowering of BMI and WHR. The HDL Cholesterols considered as good Cholesterols and lowering of BMI and WHR so this is also the beneficial effect of the test drug.
Keywords: Hyperlipidaemia, Fart-e-Tadassum-Fid-Dam, Safoof-e-Mohazzil, Atorvastatin, BMI, WHR.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.